Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for High-risk early HR-positive breast cancer, drawn from the whole corpus: 20 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
No test yet identifies the women whose relapse will come after ten years, when endocrine therapy has stopped.
Nothing recorded yet.
Also on OnCo: Treatment journeys · Survivorship planner.
Two to three years of a CDK4/6 inhibitor is costly and its overall survival benefit is not yet proven.
Adherence to endocrine therapy falls to about half by five years because of joint pain, hot flushes and sexual side effects.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Side effects by symptom · Immune-related side effects · Toxicity compare · Survivorship planner.
Premenopausal women with node-positive disease still gain from chemotherapy in RxPONDER, and whether ovarian suppression could replace it is unanswered.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 21 changes by month →When this page itself was last checked or edited.
iDFS ~30% relative reduction (HR ~0.
A milestone in how this cancer is treated.
iDFS HR 0.
A milestone in how this cancer is treated.
iDFS HR 0.